What LEO Pharma UK/IE does

LEO Pharma UK/IE is the UK and Ireland operating subsidiary of Denmark-based LEO Pharma A/S, a privately-held pharmaceutical company focused exclusively on medical dermatology and thrombosis. Founded in 1908 in Copenhagen and operating in the UK and Ireland for over 60 years (Ireland manufacturing since 1958, UK operations since 1960), the entity runs its UK commercial headquarters from Maidenhead and maintains manufacturing facilities in Dublin (topical dermatology products: ointments, creams, gels, aerosols for global distribution) and Cork (heparin purification API plant). The UK/IE workforce spans 150+ commercial staff plus 550 manufacturing employees across the Irish sites.

The product portfolio is bifurcated across dermatology and critical care. Dermatology spans established topical brands (Dovobet, Dovonex, Enstilar, Fucidin/Fucibet/Fucidin H, Protopic, Skinoren, Finacea, Travocort) and newer specialty biologics and small molecules (Adtralza/tralokinumab, Anzupgo/delgocitinib, Kyntheum/brodalumab). The critical care franchise centers on heparin-based anticoagulants (Heparin injection BP, innohep/tinzaparin sodium) and Protamine Sulphate for heparin reversal. R&D is conducted at the parent level, powered by more than 750 scientists globally with a stated cadence of one innovative dermatology launch every 2-3 years.

The business model is prescription pharmaceutical sales to publicly-funded health systems. Products are distributed through NHS trusts, Irish health system channels, and pharmacy distribution networks. The go-to-market is enterprise field sales targeting dermatologists, GPs, and specialists, augmented by NHS collaborative working projects (e.g., the Nurse-Led Atopic Dermatitis Service), patient organization partnerships (National Eczema Society, The Psoriasis Association, Irish Skin Foundation, Allergy UK), and transparent clinical trial disclosure. Marketing activities are governed by ABPI (UK) and IPHA (Ireland) Codes of Practice. Ownership is held by the LEO Foundation since 1986, with Nordic Capital providing external investment in 2021 to support the 2030 growth strategy.

Name

LEO Pharma UK/IE

Legal name

LEO Pharma UKIE

Website

https://leo-pharma.co.uk

Company type

Private

Founded year

1908

Operating status

Operating

Short description

LEO Pharma UK/IE is the UK and Ireland subsidiary of Denmark's LEO Pharma A/S, selling prescription dermatology treatments (Dovobet, Adtralza, Fucidin, Anzupgo) and heparin-based critical care medicines to NHS, Irish health system, and pharmacies via field sales, with manufacturing in Dublin and Cork, Ireland.

Ownership category

akta.pro rank

Product category

Prescription Dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Topical & Dermatology Generics (HLAIABAE)

Keywords

• Medical dermatology treatments
• Topical dermatology pharmaceuticals
• Biologic dermatology injections
• Anticoagulant critical care medicines
• Prescription skin care products

Headquarters

HQ city

Maidenhead

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: LEO Pharma generates revenue through the sale of prescription pharmaceutical products including dermatology treatments (topical creams, ointments, gels, aerosols, biologic injections) and critical care medicines (heparin, tinzaparin sodium). Products are supplied through healthcare systems, pharmacies, and directly to NHS trusts.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

LEO Pharma UK/IE is the UK and Ireland subsidiary of LEO Pharma A/S, selling a portfolio of prescription pharmaceutical products focused on medical dermatology and critical care. The dermatology range includes topical formulations (ointments, creams, gels, foams, aerosols) and biologic injections for psoriasis, atopic dermatitis, chronic hand eczema, and other inflammatory skin conditions. The critical care portfolio centres on heparin-based anticoagulants and the tinzaparin product innohep. Manufacturing is performed at sites in Dublin and Cork, Ireland, supplying UK and Irish healthcare systems.

Product overview

LEO Pharma UK/IE is a research-based pharmaceutical company operating as the UK and Ireland subsidiary of LEO Pharma A/S (headquartered in Denmark). The company specializes in medical dermatology and critical care medicine, offering a portfolio of topical treatments (ointments, creams, gels, foams, aerosols), biologic injections, and anticoagulant medications. Their dermatology portfolio includes established products like Dovobet, Dovonex, Enstilar, Fucidin, Protopic, and Skinoren for conditions such as psoriasis and atopic eczema, along with newer biologics Adtralza (tralokinumab) and Anzupgo (delgocitinib). Their critical care portfolio centers on heparin-based anticoagulant products including innohep (tinzaparin sodium). The company operates manufacturing facilities in Dublin (established 1958) and Cork, Ireland (established 1987).

Differentiator

Problem solved

Functional benefit

Products and services

• Adtralza (tralokinumab) Adtralza is a biologic injection (tralokinumab) available as a 300 mg pre-filled pen and 150 mg pre-filled syringe, indicated for the treatment of atopic dermatitis (eczema). It is prescribed by dermatologists and other qualified healthcare professionals.
• Anzupgo (delgocitinib) Anzupgo is a 20 mg/g cream formulation of delgocitinib used for the treatment of dermatological conditions such as chronic hand eczema.
• Dovobet (calcipotriol + betamethasone dipropionate) Dovobet is a topical gel and ointment combining calcipotriol (a vitamin D analog) with betamethasone dipropionate (a corticosteroid) for the treatment of psoriasis vulgaris.
• Dovonex (calcipotriol) Dovonex is a topical calcipotriol ointment (vitamin D analog) used for the treatment of plaque psoriasis.
• Enstilar (calcipotriol + betamethasone dipropionate) Enstilar is a cutaneous foam combining calcipotriol with betamethasone dipropionate for topical application in psoriasis treatment.
• Finacea (azelaic acid) Finacea is an azelaic acid gel used for the topical treatment of inflammatory skin conditions such as rosacea and acne.
• Fucibet (fusidic acid + betamethasone) Fucibet is a cream combining fusidic acid (antibiotic) with betamethasone valerate (corticosteroid) for the treatment of infected inflammatory skin conditions.
• Fucidin (fusidic acid/sodium fusidate) Fucidin is a range of topical and oral formulations containing fusidic acid or sodium fusidate (cream, ointment, oral suspension, tablets) for the treatment of bacterial skin infections.
• Fucidin H (fusidic acid + hydrocortisone) Fucidin H is a cream combining fusidic acid with hydrocortisone acetate, an antibiotic and mild corticosteroid combination for infected inflammatory skin conditions.
• Kyntheum (brodalumab) Kyntheum is a 210 mg solution for injection containing brodalumab, a biologic medication for the treatment of moderate-to-severe plaque psoriasis.
• Protopic (tacrolimus) Protopic is a tacrolimus ointment available in 0.03% and 0.1% concentrations, used as a topical calcineurin inhibitor for the treatment of atopic dermatitis.
• Skinoren (azelaic acid) Skinoren is a topical azelaic acid cream used for the treatment of inflammatory skin conditions such as acne and rosacea.
• Travocort (diflucortolone + isoconazole) Travocort combines diflucortolone valerate (corticosteroid) with isoconazole nitrate (antifungal) for the treatment of inflammatory fungal skin infections.
• Heparin injection BP Heparin injection BP is an anticoagulant medication available in 1,000 IU and 5,000 IU formulations for use in critical care medicine for the prevention and treatment of thrombotic events.
• innohep (tinzaparin sodium) innohep is a range of tinzaparin sodium low molecular weight heparin formulations available in vials and pre-filled syringes at 10,000–20,000 IU/ml, used as an anticoagulant for the treatment of deep vein thrombosis and related conditions.
• Protamine Sulphate LEO Pharma Protamine Sulphate LEO Pharma is a 1400 anti-heparin IU/ml solution for injection and infusion, used to reverse the anticoagulant effects of heparin.

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Allergy UKcoreStrategic or Co-development PartnerAllergy UK collaborated with LEO Pharma on the Chronic Hand Eczema (CHE) Patient Impact Report. A multi-disciplinary taskforce was created including dermatology, general practice, and Allergy UK representation to explore the impact of CHE on people's lives.
• National Eczema SocietymajorStrategic or Co-development PartnerLEO Pharma collaborates with National Eczema Society on initiatives that communicate the impact of skin conditions to improve understanding of what it is like to live with skin conditions.
• The Psoriasis AssociationmajorStrategic or Co-development PartnerLEO Pharma collaborates with The Psoriasis Association on initiatives that communicate the impact of skin conditions to improve understanding of what it is like to live with skin conditions.
• The Irish Skin FoundationmajorStrategic or Co-development PartnerLEO Pharma collaborates with The Irish Skin Foundation on initiatives that communicate the impact of skin conditions to improve understanding of what it is like to live with skin conditions.
• NHS (Nurse-Led Atopic Dermatitis Service)coreStrategic or Co-development PartnerLEO Pharma has an ongoing Collaborative Working Project with NHS on the Nurse-Led Atopic Dermatitis (NuLAD) Service. Joint Working Projects in the UK aim to advance dermatology care standards.
• Navex GlobalminorOthersNavex Global manages the LEO WhistleBlower Hotline, providing a confidential reporting channel for unethical behaviour within LEO Pharma. Available 24 hours a day, 365 days a year in multiple languages.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Global pharmaceutical major whose Dupixent (dupilumab) franchise is the market-leading biologic in moderate-to-severe atopic dermatitis and adjacent type-2 inflammatory indications. Directly competes with LEO Pharma's Adtralza (tralokinumab) and other IL-13/IL-4 pathway products in UK/Ireland and globally.
• AbbVie: Global pharmaceutical major with one of the largest immunology/dermatology franchises (Humira, Skyrizi, Rinvoq) treating psoriasis, atopic dermatitis, and related inflammatory skin conditions. Comparable as a broad-incumbent competitor to LEO Pharma's psoriasis and atopic dermatitis offerings.
• Eli Lilly: Global pharmaceutical company with Taltz (ixekizumab) and other IL-17/IL-23 pathway biologics in psoriasis and emerging inflammatory skin indications. Comparable as a broad-incumbent biologic competitor to LEO Pharma's Kyntheum and other psoriasis offerings in UK/Ireland.

Direct peers

• Almirall: Spanish specialty pharmaceutical company focused on medical dermatology, with European commercial footprint and a portfolio of branded topical and systemic treatments. Comparable to LEO Pharma UK/IE as a similarly-sized European dermatology specialty peer with overlapping therapeutic areas (psoriasis, actinic keratosis, atopic dermatitis).
• Galderma: World's largest independent dermatology-focused specialty pharmaceutical company with a broad portfolio across prescription dermatology, aesthetics, and consumer skin health. Directly comparable to LEO Pharma UK/IE as both are prescription dermatology specialists competing for the same prescriber base across psoriasis, atopic dermatitis, and acne/rosacea.
• Pierre Fabre Dermatologie: French pharmaceutical group's dermatology division developing and commercialising branded prescription treatments across skin diseases. Comparable to LEO Pharma UK/IE as a European dermatology specialty competitor with overlapping therapeutic categories and a similar mix of topical and systemic products.

Emerging players

• UCB: Belgian biopharmaceutical company with a growing dermatology/immunology biologic franchise (Cimzia, bimekizumab) targeting psoriasis and related inflammatory skin conditions. Comparable as a European-based immunology/dermatology biologic competitor with overlapping prescribers to LEO Pharma's Kyntheum.
• Dermavant Sciences: Dermatology-focused biotech commercialising newer topical and systemic therapies including tapinarof and other inflammatory skin disease treatments. Comparable as a dermatology specialist competing for the same chronic inflammatory skin disease prescribers that LEO addresses with Dovobet, Protopic, and Anzupgo.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/leopharmaukie

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LEO Pharma UK/IE